ЗАКЛЮЧЕНИЕ

1. Instruktsiya po meditsinskomu primeneniyu preparata Eksalief RU-LP 001-263.

2. Karlov V.A. Epilepsiya u detei i vzroslykh zhenshchin i muzhchin detei i vzroslykh zhenshchin i muzhchin. Izd. «Meditsina». 2010. 720 s.

3. Bialer M., Soares-da-Silva P. Pharmaco-kinetics and drug interactions of eslicarbazepine acetate. Epilepsia. 2012; 53: 935-46.

4. Brodie M.J., Mintzer S., Pack A.M. et al. Enzyme induction with antiepileptic drugs: cause for concern? Epilepsia. 2013; 54: 11-27.

5. Brodie M.J., Lerche H., Gil-Nagel A. et al. Efficacy and safety of adjunctive ezogabine (retigabine) in refractory partial epilepsy. Neurology. 2010; 75: 1817-24.

6. Chung S., Ben-Menachem E., Sperling M.R. et al. Examining the clinical utility of lacosamide: pooled analyses of three phase II/III clinical trials. CNS Drugs 2010; 24: 1041-54.

7. Elger C., Halász P., Maia J. et al. Efficacy and safety of eslicarbazepine acetate as adjunctive treatment in adults with refractory partial-onset seizures: a randomized, double-blind, placebocontrolled, parallel-group phase III study. Epilepsia. 2009; 50: 454-63.

8. Eslicarbazepine acetate: who needs it? A Progress in Neurology and Psychiatry Supplement. Date of preparation January 2013. ZebinixUK2263.

9. French J.A., Abou-Khalil B., Leroy R.F. et al. Randomized, double-blind, placebocontrolled trial of ezogabine (retigabine) in partial epilepsy. Neurology. 2011; 76: 1555-63.

10. Gil-Nagel A., Elger C., Ben-Menachem E. et al. Efficacy and safety of eslicarbazepine acetate as add-on treatment in patients with focalonset seizures: integrated analysis of pooled data from double-blind phase III clinical studies. Epilepsia. 2013; 54: 98-107.

11. Halász P., Cramer J.A., Hodoba D. et al. Long-term efficacy and safety of eslicarbazepine acetate: results of a 1-year openlabel extension study in partial-onset seizures in adults with epilepsy. Epilepsia. 2010; 51:1963-9.

12. Hauser W.F. The descriptive epidemiology of epilepsy. Epilepsy: translational, clinical and social aspects. Moscow. 2013; 83-117.

13. Hufnagel A., Ben-Menachem E., Gabbai A.A. et al. Long-term safety and efficacy of eslicarbazepine acetate as adjunctive therapy in the treatment of partial-onset seizures in adults with epilepsy: results of a 1-year openlabel extension study. Epilepsy Res. 2012; [Epub ahead of print]. https://doi.org/10.1016/j. eplepsyres.2012.07.014].

14. Johannessen S.I., Landmark C.J. Antiepileptic drug interactions: principles and clinical implications. Curr Neuro -pharmacol. 2010; 8: 254-67.

15. Johannessen S.I., Landmark C.J. Antiepileptic drug interactions: principles and clinical implications. Curr Neuro -pharmacol. 2010; 8: 254-67.

16. Nunes T., Rocha J., Falcão A. et al. Steadystate plasma and cerebrospinal fluid pharmacokinetics and tolerability of eslicarbazepine acetate and oxcarbazepine in healthy volunteers. Epilepsia. 2013; 54: 108-116.

17. Reimers A., Brodtkorb E. Secondgeneration antiepileptic drugs and pregnancy: a guide for clinicians. Exp Rev Neurother. 2012; 12: 707-17.

18. Wolf P. Praxisbuch Epilepsien. Diagnostic, Behandlung, Rehabilitation - Kohlhammer, Stuttgart. 2003; 394 s.

19. Zebinix Summary of Product Characteristics, August 2012.

20. Peltola J., Holtkamp M. et al. Practical guidance and considerations for transitioning patients from oxcarbazepine or carbamazepine to eslicarbazepine acetate - Expert opinion. Epilepsy & Behavior 50 2015; 46-49.